S. Keir

发表

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

D. Busam, R. Strausberg, G. Parmigiani, 2008, Science.

The integrated landscape of driver genomic alterations in glioblastoma

Raul Rabadan, Peter Canoll, Jeffrey N. Bruce, 2013, Nature Genetics.

The Genetic Landscape of the Childhood Cancer Medulloblastoma

Zev A. Binder, G. Parmigiani, M. Berger, 2011, Science.

Distress persists in long-term brain tumor survivors with glioblastoma multiforme

S. Keir, E. Lipp, H. Friedman, 2008, Journal of cancer survivorship : research and practice.

Initial testing of the investigational NEDD8‐activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing (stage 1) of the multi‐targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program

Peter J Houghton, John M Maris, Richard Gorlick, 2010, Pediatric blood & cancer.

Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development

K. Hoadley, S. Keir, D. Bigner, 2015, Journal of neurochemistry.

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2009, Pediatric blood & cancer.

The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion

S. Keir, D. Bigner, H. Friedman, 2007, Molecular Cancer Therapeutics.

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma

R. McLendon, S. Keir, D. Bigner, 2018, Clinical Cancer Research.

Initial testing of cisplatin by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models

S. Keir, H. Friedman, K. Di, 2014, Journal of Neuro-Oncology.

Initial testing (stage 1) of the IGF‐1 receptor inhibitor BMS‐754807 by the pediatric preclinical testing program

Richard Gorlick, S. Keir, J. Maris, 2011, Pediatric blood & cancer.

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

R. McLendon, S. Keir, D. Bigner, 2005, Molecular cancer therapeutics.

Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer.

M. Dewhirst, S. Keir, S. Freedland, 2010, Journal of applied physiology.

Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.

M. Dolan, S. Keir, D. Bigner, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents

C. B. Hare, S. Keir, D. Bigner, 1998, Cancer Chemotherapy and Pharmacology.

O 6-Benzylguanine-mediated Enhancement of Chemotherapy 1

M. Dolan, S. Keir, D. Bigner, 2002 .

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

S. Keir, D. Bigner, H. Friedman, 2013, Journal of neurosurgery.

Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas.

G. Mills, K. Flaherty, S. Keir, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts

C. B. Hare, S. Keir, D. Bigner, 1996, Cancer Chemotherapy and Pharmacology.

The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival

K. Yeom, S. Keir, D. Bigner, 2017, Neuro-oncology.

Affinity-matured recombinant immunotoxin targeting gangliosides 3′-isoLM1 and 3′,6'-isoLD1 on malignant gliomas

I. Pastan, S. Keir, D. Bigner, 2013, mAbs.

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2009, Pediatric blood & cancer.

Levels of Stress and Intervention Preferences of Caregivers of Brain Tumor Patients

S. Keir, 2007, Cancer nursing.

Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2015, Pediatric blood & cancer.

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft

C. B. Hare, S. Keir, D. Bigner, 1997, Cancer Chemotherapy and Pharmacology.

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT‐330): A report from the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2016, Pediatric blood & cancer.

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2009, Pediatric blood & cancer.

O6-Benzylguanine-mediated enhancement of nitrosourea activity in Mer− central nervous system tumor xenografts – implications for clinical trials

S. Keir, D. Bigner, H. Friedman, 2000, Cancer Chemotherapy and Pharmacology.

Modulation of cyclophosphamide activity by O 6-alkylguanine-DNA alkyltransferase

M. Dolan, S. Keir, D. Bigner, 1999, Cancer Chemotherapy and Pharmacology.

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

[Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma.

S. Keir, M. Zalutsky, G. Vaidyanathan, 2010, Current radiopharmaceuticals.

Initial testing of topotecan by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.

R. McLendon, S. Keir, D. Bigner, 2017, Archives of pathology & laboratory medicine.

Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status

S. Keir, D. Bigner, D. Ashley, 2018, Journal of Neuro-Oncology.

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors

I. Pastan, S. Keir, D. Bigner, 2019, PloS one.

Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program

S. Keir, P. Houghton, C. Morton, 2012, Pediatric blood & cancer.

Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts

S. Keir, D. Bigner, P. Houghton, 2000, Cancer Chemotherapy and Pharmacology.

Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.

S. Keir, D. Bigner, K. Mishima, 2010, Nuclear medicine and biology.

Combination testing (Stage 2) of the Anti‐IGF‐1 receptor antibody IMC‐A12 with rapamycin by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors

S. Keir, D. Bigner, H. Friedman, 1998, Cancer Chemotherapy and Pharmacology.

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Initial testing of dasatinib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells

R. McLendon, S. Keir, Yiping He, 2022, bioRxiv.

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft

S. Keir, D. Bigner, H. Friedman, 2005, Molecular Cancer Therapeutics.

Initial testing of VS‐4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2017, Pediatric blood & cancer.

The emerging role of irinotecan (CPT‐11) in the treatment of malignant glioma in brain tumors

S. Keir, P. Houghton, H. Friedman, 2003, Cancer.

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Repurposing clemastine to target glioblastoma cell stemness

R. McLendon, S. Keir, D. Bigner, 2022, bioRxiv.

Running Head: EXERCISE AND BREAST CANCER Effect of Aerobic Exercise on Tumor Physiology in an Animal Model of Human Breast Cancer

M. Dewhirst, S. Keir, J. Herndon, 2009 .

Enhancement of melphalan activity by inhibition of DNA polymerase-α and DNA polymerase-β

S. Keir, D. Bigner, H. Friedman, 1996, Cancer Chemotherapy and Pharmacology.

Initial testing of lenalidomide by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Initial testing (Stage 1) of the antibody‐maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts

S. Keir, D. Bigner, P. Houghton, 2004, Cancer Chemotherapy and Pharmacology.

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation

G. Reifenberger, S. Keir, D. Bigner, 2023, Journal for ImmunoTherapy of Cancer.

Busulfan therapy of central nervous system xenografts in athymic mice

S. Keir, D. Bigner, H. Friedman, 2004, Cancer Chemotherapy and Pharmacology.

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation.

R. McLendon, A. Friedman, S. Murphy, 2019, Cancer research.

Recombinant anti‐podoplanin (NZ‐1) immunotoxin for the treatment of malignant brain tumors

I. Pastan, S. Keir, D. Bigner, 2013, International journal of cancer.

Activity of temozolomide in the treatment of central nervous system tumor xenografts.

M. Dolan, S. Keir, D. Bigner, 1995, Cancer research.

Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy

R. McLendon, I. Pastan, S. Keir, 2013, Clinical Cancer Research.

Repurposing clemastine to target glioblastoma cell stemness

R. McLendon, S. Keir, D. Bigner, 2022, bioRxiv.

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

Darell D. Bigner, Jie He, Roger E. McLendon, 2014, Oncotarget.

High-Grade Gliomas

C. Q. Lee, David T. W. Jones, Michael D. Brooks, 2012, Oxford Medicine Online.

Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells*

S. Keir, D. Bigner, F. Ali-Osman, 2015, The Journal of Biological Chemistry.

The pediatric preclinical testing program: Description of models and early testing results

Joseph Zeidner, Javed Khan, Jian Zhang, 2007, Pediatric blood & cancer.

Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

Peter J Houghton, John M Maris, Richard Gorlick, 2010, Pediatric blood & cancer.

Therapeutic Targeting of Ependymoma as Informed by Oncogenic Enhancer Profiling

Anne Song, Stefan M. Pfister, Paul A. Northcott, 2017, Nature.

Testing of the Akt/PKB inhibitor MK‐2206 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

S. Keir, J. Maris, P. Houghton, 2011, Cancer Chemotherapy and Pharmacology.

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ‐26481585), by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation

R. McLendon, S. Keir, Hai Yan, 2013, Oncotarget.

MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B.

R. McLendon, A. Friedman, S. Keir, 2016, Cancer cell.

Exomic Sequencing of Four Rare Central Nervous System Tumor Types

Gary L. Gallia, Yuchen Jiao, Yuxuan Wang, 2013, Oncotarget.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Peter J Houghton, John M Maris, Richard Gorlick, 2016, Cancer research.

O6-benzylguanine-mediated enhancement of chemotherapy.

Peter J Houghton, M Eileen Dolan, M. Dolan, 2002, Molecular cancer therapeutics.

Initial Testing (Stage 1) of MK‐8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2016, Pediatric blood & cancer.

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model

S. Keir, D. Bigner, H. Friedman, 2012, Journal of Neuro-Oncology.

Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.

R. McLendon, B. A. Rasheed, S. Keir, 2006, Cancer research.

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2014, Clinical Cancer Research.

HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.

R. McLendon, S. Keir, Hai Yan, 2010, Neuro-oncology.

Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233

S. Keir, D. Bigner, S. Kosanke, 2012, Journal of Neuro-Oncology.

DUKE UNIVERSITY MEDICAL CENTER CURRICULUM VITAE

Stephen Thomas Keir, S. Keir, 2013 .

Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors.

M. Dewhirst, S. Keir, D. Bigner, 2011, Anti-cancer agents in medicinal chemistry.

ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors

R. McLendon, B. A. Rasheed, S. Keir, 2005, Clinical Cancer Research.

GENETIC PROFILING IN TUMOR XENOGRAFTS FROM PAEDIATRIC GLIOMAS BY EXPRESSION AND HIGH RESOLUTION COMPARATIVE GENOMIC HYBRIDISATION MICROARRAYS

W Harkness, Thomas S. Jacques, Tracy Warr, 2008 .

Testing of the topoisomerase 1 inhibitor Genz‐644282 by the pediatric preclinical testing program

S. Keir, J. Maris, B. Teicher, 2012, Pediatric blood & cancer.

A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth.

D. Bigner, S. Keir, O. Ohmori, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2017, Pediatric blood & cancer.

miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways.

R. McLendon, A. Friedman, S. Keir, 2014, The Journal of clinical investigation.

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17‐DMAG, KOS‐1022) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

A cross sectional analysis from a single institution’s experience of psychosocial distress and health-related quality of life in the primary brain tumor population

S. Keir, E. Lipp, H. Friedman, 2017, Journal of Neuro-Oncology.

Screening for distress in patients with brain cancer using the NCCN's rapid screening measure

S. Keir, H. Friedman, O. Saleh, 2008, Psycho-oncology.

A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas

R. McLendon, K. Flaherty, S. Keir, 2021, Clinical Cancer Research.

Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice

S. Keir, D. Bigner, P. Houghton, 2001, Cancer Chemotherapy and Pharmacology.

Effect of massage therapy on stress levels and quality of life in brain tumor patients—observations from a pilot study

S. Keir, 2011, Supportive Care in Cancer.

Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.

S. Keir, D. Bigner, L. Muhlbaier, 2007, Neuro-oncology.

A Therapeutic Antibody for Cancer, Derived from Single Human B Cells.

H. Liao, B. Haynes, S. Keir, 2016, Cell reports.

Initial testing of the replication competent Seneca Valley virus (NTX‐010) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice

S. Keir, D. Bigner, H. Friedman, 2001, Cancer Chemotherapy and Pharmacology.

Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

S. Keir, P. Houghton, S. Bigner, 1997, Cancer research.

Initial testing (stage 1) of the notch inhibitor PF‐03084014, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Exercise interest and preferences among patients diagnosed with primary brain cancer

S. Keir, D. Bigner, L. Jones, 2006, Supportive Care in Cancer.

Cold Plasma Discharge Tube Enhances Anti-Tumoral Efficacy of Temozolomide

M. Keidar, S. Keir, J. Sherman, 2022, 2022 IEEE International Conference on Plasma Science (ICOPS).

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models

S. Keir, D. Bigner, H. Friedman, 2018, Journal of Neuro-Oncology.

EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.

S. Keir, F. Ali-Osman, H. Lo, 2010, Cancer letters.

Stress and long-term survivors of brain cancer

S. Keir, H. Friedman, Jonas J. Swartz, 2007, Supportive Care in Cancer.

Stress and intervention preferences of patients with brain tumors

S. Keir, H. Friedman, K. Carter, 2006, Supportive Care in Cancer.

Patterns of exercise across the cancer trajectory in brain tumor patients

D. Bigner, S. Keir, L. Jones, 2006, Cancer.

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

S. Keir, L. Rubinstein, J. Maris, 2010, Molecular Cancer Therapeutics.

Initial testing (stage 1) of SGI‐1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing of the CENP‐E inhibitor GSK923295A by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(β-D-gluco pyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts

S. Keir, D. Bigner, H. Friedman, 2001, Cancer Chemotherapy and Pharmacology.

Program preferences to reduce stress in caregivers of patients with brain tumors.

S. Keir, Jonas J. Swartz, 2007, Clinical journal of oncology nursing.

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Peter J Houghton, John M Maris, Richard Gorlick, 2013, Pediatric blood & cancer.

Initial testing of the hypoxia‐activated prodrug PR‐104 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Initial testing (stage 1) of mapatumumab (HGS‐ETR1) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2009, Pediatric blood & cancer.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

S. Keir, J. Maris, O. Hampton, 2015, Pediatric blood & cancer.

Abstract LB-353: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib.

S. Keir, J. Maris, P. Houghton, 2013 .

Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas

S. Keir, J. Huse, M. Castro, 2023, bioRxiv.

Treatment for Glioblastoma Reversing the Warburg Effect as a Metabolism

D. Bigner, S. Keir, Hai Yan, 2014 .

Abstract C206: Pediatric Preclinical Testing Program (PPTP) evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide (TMZ).

S. Keir, J. Maris, P. Houghton, 2013 .

Erratum: Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer (Journal of Applied Physiology (2010) 108: (343-348) DOI: 10.1152/japplphysiol.00424.2009)

M. Dewhirst, S. Keir, S. Freedland, 2010 .

Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer

S. Keir, D. Bigner, L. Jones, 2007, Psycho-oncology.

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Family Appraisal of Caregiving in a Brain Cancer Model

S. Keir, E. Lipp, H. Friedman, 2009 .

A novel low‐molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth

Osamu Ohmori, S. Keir, D. Bigner, 2007, Molecular carcinogenesis.

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Reversing the Warburg Effect as a Treatment for Glioblastoma*

S. Keir, Hai Yan, D. Bigner, 2013, The Journal of Biological Chemistry.

Differential levels of stress in caregivers of brain tumor patients—observations from a pilot study

S. Keir, H. Friedman, K. Carter, 2006, Supportive Care in Cancer.

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signaling

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Pilot study of the impact of massage therapy on sources and levels of distress in brain tumour patients

S. Keir, Julia R. Saling, 2012, BMJ Supportive & Palliative Care.

Affinity‐matured anti‐glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas

I. Pastan, S. Keir, D. Bigner, 2011, International journal of cancer.

Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.

S. Keir, H. Friedman, M. Zalutsky, 1996, British Journal of Cancer.

Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells

R. McLendon, S. Keir, Yiping He, 2022, bioRxiv.

O 6-Benzylguanine-mediated enhancement of nitrosourea activity in Mer ) central nervous system tumor xenografts ± implications for clinical trials

S. Keir, D. Bigner, H. Friedman, 2022 .

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Initial testing of aplidin by the pediatric pre‐clinical testing program

S. Keir, J. Maris, P. Houghton, 2009, Pediatric blood & cancer.

Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models.

S. Keir, R. Ryan, Idoia Gamez, 2010, Anticancer Research.

High grade gliomas

C. Q. Lee, David T. W. Jones, Michael D. Brooks, 2022, Progress in Brain Research.

Testing of the topoisomerase 1 inhibitor Genz‐644282 by the pediatric preclinical testing program

S. Keir, J. Maris, B. Teicher, 2012, Pediatric blood & cancer.

Recombinant anti‐podoplanin (NZ‐1) immunotoxin for the treatment of malignant brain tumors

I. Pastan, S. Keir, D. Bigner, 2013, International journal of cancer.

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

The Genetic Landscape of the Childhood Cancer Medulloblastoma

Zev A. Binder, G. Parmigiani, M. Berger, 2011, Science.

Initial testing of VNP40101M (Cloretazine®) by the pediatric preclinical testing program

S. Keir, P. Houghton, C. Morton, 2008, Pediatric blood & cancer.

Exomic Sequencing of Four Rare Central Nervous System Tumor Types

Zev A. Binder, R. McLendon, L. Wood, 2013, Oncotarget.

Combination testing (Stage 2) of the Anti‐IGF‐1 receptor antibody IMC‐A12 with rapamycin by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.

S. Keir, H. Friedman, M. Zalutsky, 1996, British Journal of Cancer.